Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.
CIGB-300 is a proapoptotic peptide-based drug that abrogates the CK2-mediated phosphorylation. This peptide has antineoplastic effect on lung cancer cells in vitro and in vivo. To understand the mechanisms involved on such anticancer activity, the NCI-H125 cell line proteomic profile after short-term incubation (45 min) with CIGB-300 was investigated. As determined by 2-DE or 2D-LC-MS/MS, 137 proteins changed their abundances more than 2-fold in response to the CIGB-300 treatment. The expression levels of proteins related to ribosome biogenesis, metastasis, cell survival and proliferation, apoptosis, and drug resistance were significantly modulated by the presence of CIGB-300. The protein translation process was the most affected (23% of the identified proteins). From the proteome analysis of the NCI-H125 cell line, novel potentialities for CIGB-300 as anticancer agent were evidenced.
Rodríguez-Ulloa
Arielis
A
Department of Bioinformatics, Center for Genetic Engineering and Biotechnology, Havana, Cuba. arielis.rodriguez@biocomp.cigb.edu.cu
Ramos
Yassel
Y
Gil
Jeovanis
J
Perera
Yasser
Y
Castellanos-Serra
Lila
L
García
Yairet
Y
Betancourt
Lázaro
L
Besada
Vladimir
V
González
Luis J
LJ
Fernández-de-Cossio
Jorge
J
Sanchez
Aniel
A
Serrano
Joem M
JM
Farina
Hernán
H
Alonso
Daniel F
DF
Acevedo
Boris E
BE
Padrón
Gabriel
G
Musacchio
Alexis
A
Perea
Silvio E
SE
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002853:Chromatography, Liquid; D016000:Cluster Analysis; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D013058:Mass Spectrometry; D010456:Peptides, Cyclic / Q000494:pharmacology*; D014176:Protein Biosynthesis / Q000187:drug effects*; D020543:Proteome / Q000032:analysis* / Q000145:classification; D040901:Proteomics / Q000379:methods*
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D020543:Proteome; C532510:CIGB-300